Endovascular Engineering develops and deploys advanced clot removal solutions for the treatment of venous thromboembolism.
Endovascular Engineering has raised $80.0M in total funding. The most recent round was Series C. The last funding was announced in April 2026.
Endovascular Engineering's investors include Norwest, S3 Ventures, Sante Ventures, Panakes Partners, Gilde Healthcare.
Endovascular Engineering is headquartered in Menlo Park, United States.
Endovascular Engineering develops and deploys advanced clot removal solutions for the treatment of venous thromboembolism.
Endovascular Engineering is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Endovascular Engineering — Funding & Investors." VCBacked, April 7, 2026, https://www.vcbacked.co/company/endovascular-engineering. Accessed September 30, 2026.
VCBacked. (2026). Endovascular Engineering — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/endovascular-engineering
{{cite web |title=Endovascular Engineering — Funding & Investors |url=https://www.vcbacked.co/company/endovascular-engineering |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated